These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 24356253)

  • 1. Pharmacokinetics of pediatric lopinavir/ritonavir tablets in children when administered twice daily according to FDA weight bands.
    Bastiaans DE; Forcat S; Lyall H; Cressey TR; Hansudewechakul R; Kanjanavanit S; Noguera-Julian A; Königs C; Inshaw JR; Chalermpantmetagul S; Saïdi Y; Compagnucci A; Harper LM; Giaquinto C; Colbers AP; Burger DM;
    Pediatr Infect Dis J; 2014 Mar; 33(3):301-5. PubMed ID: 24356253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low dose lopinavir/ritonavir tablet achieves adequate pharmacokinetic parameters in HIV-infected Thai adolescents.
    Klinklom A; Puthanakit T; Gorowara M; Phasomsap C; Kerr S; Sriheara C; Ananworanich J; Burger D; Ruxrungtham K; Pancharoen C
    Antivir Ther; 2012; 17(2):283-9. PubMed ID: 22293065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines.
    Pinto JA; Capparelli EV; Warshaw M; Zimmer B; Cressey TR; Spector SA; Qin M; Smith B; Siberry GK; Mirochnick M;
    Pediatr Infect Dis J; 2018 Feb; 37(2):e29-e35. PubMed ID: 29088027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neither branded nor generic lopinavir/ritonavir produces adequate lopinavir concentrations at a reduced dose of 200/50 mg twice daily.
    Ramautarsing RA; van der Lugt J; Gorowara M; Wongsabut J; Khongpetch C; Phanuphak P; Ananworanich J; Lange JM; Burger DM; Ruxrungtham K; Avihingsanon A
    J Acquir Immune Defic Syndr; 2012 Jan; 59(1):55-8. PubMed ID: 22027875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: implications for treatment guidelines.
    Patterson KB; Dumond JB; Prince HA; Jenkins AJ; Scarsi KK; Wang R; Malone S; Hudgens MG; Kashuba AD
    J Acquir Immune Defic Syndr; 2013 May; 63(1):51-8. PubMed ID: 23221983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations.
    Bouazza N; Foissac F; Fauchet F; Burger D; Kiechel JR; Treluyer JM; Capparelli EV; Lallemant M; Urien S
    Antivir Ther; 2015; 20(2):225-33. PubMed ID: 25279808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetic analysis of SNPs in genes involved in the pharmacokinetics and response to lopinavir/ritonavir therapy.
    López Aspiroz E; Cabrera Figueroa SE; Porras Hurtado GL; Cruz Guerrero R; Domínguez-Gil Hurlé A; Carracedo A;
    Curr Drug Metab; 2013 Sep; 14(7):729-37. PubMed ID: 24001122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.
    Pham PA; Flexner C; Parsons T; Vasist L; Fuchs E; Carson K; Agarwala S; Barditch-Crovo P
    J Acquir Immune Defic Syndr; 2007 Jun; 45(2):201-5. PubMed ID: 17414932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men.
    Umeh OC; Currier JS; Park JG; Cramer Y; Hermes AE; Fletcher CV
    J Clin Pharmacol; 2011 Dec; 51(12):1665-73. PubMed ID: 21233301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy.
    Cressey TR; Jourdain G; Rawangban B; Varadisai S; Kongpanichkul R; Sabsanong P; Yuthavisuthi P; Chirayus S; Ngo-Giang-Huong N; Voramongkol N; Pattarakulwanich S; Lallemant M;
    AIDS; 2010 Sep; 24(14):2193-200. PubMed ID: 20625263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized clinical trial comparing the pharmacokinetics of standard- and increased-dosage lopinavir-ritonavir coformulation tablets in HIV-positive pregnant women.
    Santini-Oliveira M; Estrela Rde C; Veloso VG; Cattani VB; Yanavich C; Velasque L; Torres TS; Marins LM; Pilotto JH; João EC; Gonçalves JC; Grinsztejn B
    Antimicrob Agents Chemother; 2014 May; 58(5):2884-93. PubMed ID: 24614377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children.
    Musiime V; Fillekes Q; Kekitiinwa A; Kendall L; Keishanyu R; Namuddu R; Young N; Opilo W; Lallemant M; Walker AS; Burger D; Gibb DM
    J Acquir Immune Defic Syndr; 2014 Jun; 66(2):148-54. PubMed ID: 24828266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the ACTG 5283 study.
    Luque AE; Cohn SE; Park JG; Cramer Y; Weinberg A; Livingston E; Klingman KL; Aweeka F; Watts DH
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2094-101. PubMed ID: 25624326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics and dosing regimen optimisation of lopinavir in Chinese adults infected with HIV.
    Niu WJ; Sun T; Liu L; Liu XQ; Zhang RF; Yin L; Wang JR; Jia XF; Lu HZ; Zhong MK; Jiao Z; Zhang LJ
    Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):456-465. PubMed ID: 30346663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients.
    van Heeswijk RP; Bourbeau M; Seguin I; Giguere P; Garber GE; Cameron DW
    Br J Clin Pharmacol; 2005 Apr; 59(4):398-404. PubMed ID: 15801934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children.
    Rakhmanina NY; Neely MN; Van Schaik RH; Gordish-Dressman HA; Williams KD; Soldin SJ; van den Anker JN
    Ther Drug Monit; 2011 Aug; 33(4):417-24. PubMed ID: 21743379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simplification of therapeutic drug monitoring for twice-daily regimens of lopinavir/ritonavir for HIV infection.
    Alexander CS; Montaner JS; Asselin JJ; Ting L; McNabb K; Harris M; Guillemi S; Harrigan PR
    Ther Drug Monit; 2004 Oct; 26(5):516-23. PubMed ID: 15385834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood.
    Yang J; Nikanjam M; Best BM; Pinto J; Chadwick EG; Daar ES; Havens PL; Rakhmanina N; Capparelli EV
    J Clin Pharmacol; 2018 Dec; 58(12):1604-1617. PubMed ID: 30252146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
    Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
    Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacokinetic profiles of lopinavir (LPV) in Chinese HIV-infected patients].
    Zhang X; Liu Z; Du X; Fu Q; Li T
    Zhonghua Nei Ke Za Zhi; 2015 May; 54(5):431-3. PubMed ID: 26080823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.